BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Intradigm Corporation Licenses Key Next Generation RNA Interference (RNAi) Intellectual Property From University of Massachusetts Medical School


4/9/2008 8:36:49 AM

PALO ALTO, Calif., April 9, 2008 /PRNewswire/ -- Intradigm Corporation, a leading developer of targeted, systemic RNA interference (RNAi) therapeutics, today announced that it has licensed key intellectual property (IP) covering certain efficacy-enhancing structural elements of small interfering RNA (siRNA) from the University of Massachusetts Medical School. The licensed IP includes parameters for the structural modifications for next generation siRNAs including the "Zamore Design Rules" that significantly improve the potency and efficacy of RNAi therapeutics. This licensed technology allows Intradigm to incorporate novel siRNA sequences into the company's proprietary RNAi delivery systems to create potent and effective siRNA therapeutics. The company announced this licensing agreement today as part of its presentation at the Bio-Europe Spring 2008 conference in Madrid, Spain.

The technology licensed from the University of Massachusetts Medical School provides Intradigm with a strong IP position around structural features for a next generation of siRNA molecules. Additionally, Intradigm also possesses a strong IP position surrounding biodegradable polycationic polymers for the delivery of RNAi therapeutics which the company further strengthened through its recent licensing of complementary technology from the Massachusetts Institute of Technology (MIT). This newly licensed RNAi IP estate, combined with Intradigm's innovative delivery technology and proprietary siRNA sequences, positions the company as a leader in the RNAi therapeutic space.

"By licensing this important IP from the University of Massachusetts Medical School, which we believe to be the clear center of excellence for breakthrough siRNA academic research, Intradigm has taken another critical step toward its goal of establishing itself as a leader in the development and commercialization of novel RNAi therapeutics," said Mohammad Azab, M.D., president and chief executive officer of Intradigm. "We have established an impressive IP portfolio that spans the areas of siRNA structure and sequence, as well as RNAi delivery, providing us a distinct competitive advantage enjoyed by very few other companies."

"We are keenly aware of the critical role that the fundamental RNAi research being conducted in our labs may play in ultimately bringing novel RNAi therapeutics to patients who desperately need them," stated James P. McNamara, Ph.D., Executive Director of the Office of Technology Management at the University of Massachusetts Medical School. "For this reason, we are driven to align with leaders in the RNAi therapeutic space, such as Intradigm, to provide them access to our intellectual property and support their important drug development efforts. We are eager to witness Intradigm's progress and excited at that prospect of our IP playing a central role in the company's future success."

ABOUT THE RNAi NANOPLEX DELIVERY TECHNOLOGY

To address the issue of effective and targeted delivery of RNAi therapeutics, Intradigm has developed and in-licensed an extensive intellectual property portfolio around its proprietary RNAi Nanoplex (NPX) delivery technology. The RNAi NPX delivery technology is a modular, multi-component delivery vector that carries active siRNA molecules in its core with the flexibility to attach a Polyethylene Glycol (PEG) layer and/or a targeting ligand to the polymer-siRNA NPX to improve circulation half life and achieve selective distribution to the target tissue. At the core of the RNAi NPX delivery technology is Intradigm's proprietary peptide-based biodegradable polymer known as PolyTran(TM). PolyTran enables safe systemic delivery of the siRNAs. Additionally, this platform is unique in its ability to offer tissue specific targeting of siRNA through the attachment of specific ligands directed to target cell receptors. An additional key strength of the RNAi NPX delivery technology is its ability to incorporate multiple siRNAs in a single drug product. These multi-targeted therapeutics can simultaneously silence several mRNAs that represent parallel or synergistic elements of the same disease pathway resulting in a more comprehensive and/or novel therapeutic potential.

Recent technology licensing agreements with institutions such as the University of Massachusetts Medical School and the Massachusetts Institute of Technology have enhanced Intradigm's existing intellectual property portfolio and provided Intradigm with the rights and know-how to leverage a broad family of polymers and polymer structures, as well as next generation siRNA structures, in connection with its RNAi Nanoplex delivery technology.

ABOUT INTRADIGM

Intradigm is a private biotechnology company dedicated to the development of targeted, systemic RNA interference (RNAi) therapeutics for the treatment of serious diseases with an initial focus on oncology.

At present, Intradigm is working to build a high-value internal pipeline of RNAi oncology therapeutics, and is actively advancing its lead drug candidate, ICS-283, for a variety of cancer indications. The company is pursuing a comprehensive integrated RNAi therapeutic development strategy that incorporates advanced RNAi delivery technology, RNAi structural technology and novel, proprietary therapeutic siRNA sequences. For more information on Intradigm, please visit http://www.intradigm.com.

ABOUT THE UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL

The University of Massachusetts Medical School, one of the fastest growing academic health centers in the country, has built a reputation as a world-class research institution, consistently producing noteworthy advances in clinical and basic research. The Medical School attracts more than $179 million in research funding annually, 80 percent of which comes from federal funding sources. The work of UMMS researcher Craig Mello, PhD, an investigator of the prestigious Howard Hughes Medical Institute (HHMI), and his colleague Andrew Fire, PhD, then of the Carnegie Institution of Washington, toward the discovery of RNA interference was awarded the 2006 Nobel Prize in Physiology or Medicine and has spawned a new and promising field of research, the global impact of which may prove astounding. UMMS is the academic partner of UMass Memorial Health Care, the largest health care provider in Central Massachusetts. For more information, visit http://www.umassmed.edu.

CONTACT: Phil Haworth of Intradigm Corporation, +1-650-855-1514,
phaworth@intradigm.com; or Alison Duffy of UMMS, +1-508-856-2000,
alison.duffy@umassmed.edu; or investors, Stephanie Diaz, +1-415-675-7400
sdiaz@vidacommunication.com, or media, Tim Brons, +1-415-675-7402,
tbrons@vidacommunication.com, both of Vida Communication for Intradigm
Corporation

Web site: http://www.intradigm.com/
http://www.umassmed.edu/


Read at BioSpace.com

Related News

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->